Free Trial

Fate Therapeutics (FATE) Competitors

Fate Therapeutics logo
$1.47 -0.07 (-4.55%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$1.47 0.00 (0.00%)
As of 10/17/2025 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FATE vs. RZLT, NRIX, DAWN, AKBA, OLMA, TYRA, TERN, TBPH, ARVN, and ERAS

Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Rezolute (RZLT), Nurix Therapeutics (NRIX), Day One Biopharmaceuticals (DAWN), Akebia Therapeutics (AKBA), Olema Pharmaceuticals (OLMA), Tyra Biosciences (TYRA), Terns Pharmaceuticals (TERN), Theravance Biopharma (TBPH), Arvinas (ARVN), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

Fate Therapeutics vs. Its Competitors

Rezolute (NASDAQ:RZLT) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Rezolute has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,025.05%. Fate Therapeutics' return on equity of -50.95% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
RezoluteN/A -65.03% -58.86%
Fate Therapeutics -2,025.05%-50.95%-36.76%

Rezolute has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500.

83.0% of Rezolute shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 14.8% of Rezolute shares are held by company insiders. Comparatively, 5.5% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Fate Therapeutics had 4 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Fate Therapeutics and 1 mentions for Rezolute. Fate Therapeutics' average media sentiment score of 0.04 beat Rezolute's score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rezolute
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Fate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rezolute currently has a consensus target price of $14.50, suggesting a potential upside of 66.86%. Fate Therapeutics has a consensus target price of $3.30, suggesting a potential upside of 124.49%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rezolute
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Fate Therapeutics
1 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Rezolute has higher earnings, but lower revenue than Fate Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RezoluteN/AN/A-$74.41M-$0.97-8.96
Fate Therapeutics$8.47M20.02-$186.26M-$1.45-1.01

Summary

Fate Therapeutics beats Rezolute on 9 of the 16 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

MetricFate TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$169.54M$3.44B$6.19B$10.56B
Dividend YieldN/A2.27%5.70%4.81%
P/E Ratio-1.0123.0185.5427.13
Price / Sales20.02481.75608.39130.24
Price / CashN/A46.9237.1060.81
Price / Book0.5310.4112.236.52
Net Income-$186.26M-$52.77M$3.33B$276.93M
7 Day Performance-10.09%2.31%1.17%1.93%
1 Month Performance52.76%12.59%6.85%2.19%
1 Year Performance-54.49%11.18%58.93%34.62%

Fate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FATE
Fate Therapeutics
4.1649 of 5 stars
$1.47
-4.5%
$3.30
+124.5%
-54.5%$169.54M$8.47M-1.01550
RZLT
Rezolute
2.1098 of 5 stars
$8.07
-2.4%
$14.50
+79.7%
+79.2%$751.15MN/A-8.3240
NRIX
Nurix Therapeutics
1.9028 of 5 stars
$9.72
-0.4%
$27.93
+187.3%
-60.7%$750.38M$54.55M-3.27300Trending News
Analyst Forecast
Analyst Revision
DAWN
Day One Biopharmaceuticals
3.1374 of 5 stars
$7.19
-0.7%
$25.29
+251.7%
-52.0%$741.61M$131.16M-7.5760Gap Down
AKBA
Akebia Therapeutics
3.4362 of 5 stars
$2.78
+1.1%
$6.75
+142.8%
+118.7%$729.15M$160.18M-16.35430
OLMA
Olema Pharmaceuticals
3.1382 of 5 stars
$10.75
+1.7%
$23.33
+117.1%
-24.7%$725.47MN/A-5.4370News Coverage
Gap Down
TYRA
Tyra Biosciences
2.5089 of 5 stars
$14.36
+6.2%
$31.86
+121.8%
-46.9%$720.58MN/A0.0020
TERN
Terns Pharmaceuticals
4.0606 of 5 stars
$8.20
+0.6%
$15.49
+88.9%
+13.5%$713.22MN/A-7.8840News Coverage
Analyst Forecast
TBPH
Theravance Biopharma
3.0666 of 5 stars
$13.92
-0.5%
$23.00
+65.2%
+62.0%$704.55M$64.38M58.00110News Coverage
ARVN
Arvinas
3.5034 of 5 stars
$9.80
+3.6%
$16.29
+66.2%
-64.9%$694.53M$263.40M-9.70420Analyst Downgrade
Gap Down
High Trading Volume
ERAS
Erasca
2.8721 of 5 stars
$2.40
-0.4%
$3.71
+54.8%
-16.8%$683.65MN/A-5.33120News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:FATE) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners